The devastating impact of Batten disease and the fight for a life-changing drug.
A parent's worst nightmare
Lucy and Mike's world was turned upside down when their children, Ollie and Amelia, were diagnosed with Batten disease. This rare and devastating condition robs children of their abilities and their quality of life. But a glimmer of hope emerged in the form of a drug trial, offering a potential lifeline.
A dramatic transformation
The drug, known as Brineura, had an incredible impact on Ollie and Amelia. It slowed the progression of the disease, giving them a fantastic quality of life. Lucy described it as a game-changer, a gift of extra years. But the high cost of the treatment became a major hurdle.
The cost controversy
Here's where it gets controversial: the recommended price for Brineura is a staggering £522,782 per person per year. While the NHS negotiates a discount, NICE (the National Institute for Health and Care Excellence) has consistently questioned the long-term benefits. They argue that the evidence is not sufficient to justify the cost.
A battle for access
Hundreds of parents, including Lucy and Mike, fought tirelessly to secure funding for this drug. They argue that the benefits to their children are undeniable and worth every penny. But NICE's decision, published recently, stated that despite the transformative nature of the treatment, it is not recommended due to a lack of long-term effectiveness data.
A heartbreaking decision
Lucy and Mike faced an incredibly difficult choice last August. Amelia started experiencing adverse reactions to the infusions, and her device malfunctioned, requiring more brain surgery. They made the heart-wrenching decision to take their children off the treatment. Ollie and Amelia, now teenagers, have been living without the infusions for six months, but their parents notice a lasting effect, even without the drug.
The unknown future
No one can predict what lies ahead for Ollie, Amelia, and other children with Batten disease. Lucy and Mike are determined to make every day count, creating special moments as a family. They know that one day, their children's health may decline rapidly, so they cherish each moment.
A fight for the future
Despite the personal toll, Lucy and Mike refuse to give up. They continue their battle, not just for their own children, but for future generations. They are exploring the possibility of a judicial review, determined to secure access to this life-changing drug. As Mike puts it, "This is hope."
And this is the part most people miss: the impact of rare diseases extends far beyond the affected individuals. It's a fight for families, for communities, and for a better future. So, what do you think? Is the cost of this drug justified, or should we prioritize other treatments? We'd love to hear your thoughts in the comments.
